RPTX Stock Price, Repare Therapeutics Inc Quote, Chart

Market Summary

USD3.19+0.04

Delayedas of 22 Apr 2024, 12:09 pm

1.27%

RPTX Stock Price

View Fullscreen

RPTX RSI Chart

RPTX Valuation

Market Cap

132.9M

Price/Earnings (Trailing)

-1.42

Price/Sales (Trailing)

2.6

EV/EBITDA

-0.22

Price/Free Cashflow

-1.03

RPTX Price/Sales (Trailing)

RPTX Profitability

EBT Margin

-201.79%

Return on Equity

-44.23%

Return on Assets

-36.94%

Free Cashflow Yield

-97.16%

RPTX Fundamentals

RPTX Revenue

Revenue (TTM)

51.1M

Rev. Growth (Yr)

-28.31%

Rev. Growth (Qtr)

504.31%

RPTX Earnings

Earnings (TTM)

-93.8M

Earnings Growth (Yr)

11.46%

Earnings Growth (Qtr)

-48.47%

Breaking Down RPTX Revenue

52 Week Range

3.1013.85

(Low)(High)

Last 7 days

-13.1%

Last 30 days

-39.8%

Last 90 days

-48.4%

Trailing 12 Months

-66.5%

How does RPTX drawdown profile look like?

RPTX Financial Health

Current Ratio

6.24

RPTX Investor Care

Shares Dilution (1Y)

0.25%

Diluted EPS (TTM)

-2.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	111.7M	91.5M	71.3M	51.1M
2022	7.8M	49.2M	90.5M	131.8M
2021	2.0M	3.9M	5.7M	7.6M
2020	0	0	0	135.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Repare Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	zinda michael	sold	-1,910	4.66	-410	evp, chief scientific officer
Apr 01, 2024	forte steve	sold	-3,637	4.61	-789	evp, chief financial officer
Apr 01, 2024	segal lloyd mitchell	sold	-11,533	4.63	-2,491	president and ceo
Apr 01, 2024	koehler maria	sold	-1,398	4.66	-300	evp, chief medical officer
Mar 28, 2024	forte steve	sold	-3,811	4.62	-825	evp, chief financial officer
Mar 28, 2024	zinda michael	sold	-2,088	4.64	-450	evp, chief scientific officer
Mar 28, 2024	segal lloyd mitchell	sold	-12,243	4.62	-2,650	president and ceo
Mar 28, 2024	koehler maria	sold	-2,320	4.64	-500	evp, chief medical officer
Mar 27, 2024	zinda michael	sold	-2,079	4.62	-450	evp, chief scientific officer
Mar 27, 2024	forte steve	sold	-3,811	4.62	-825	evp, chief financial officer

Which funds bought or sold RPTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	ARK Investment Management LLC	reduced	-4.17	-7,862,570	12,734,800	0.09%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	301	157,924	257,095	0.01%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-16.52	-449,338	457,411	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-10.06	-354,817	422,494	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-206,000	-	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	524	774,000	1,054,000	0.09%
Feb 15, 2024	Blue Owl Capital Holdings LP	new	-	22,794,200	22,794,200	5.45%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	207,576	207,576	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-86.93	-45,000	4,000	-%
Feb 15, 2024	Legal & General Group Plc	reduced	-94.46	-148,696	5,154	-%

Are Funds Buying or Selling RPTX?

Are funds buying RPTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPTX

No. of Funds

Unveiling Repare Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	7.41%	3,122,499	SC 13G
Feb 14, 2024	deep track capital, lp	7.10%	2,992,731	SC 13G/A
Feb 14, 2024	redmile group, llc	5.1%	2,148,748	SC 13G/A
Jan 29, 2024	ark investment management llc	6.70%	2,821,560	SC 13G/A
Nov 17, 2023	biotechnology value fund l p	12.6%	5,309,432	SC 13D/A
Nov 03, 2023	biotechnology value fund l p	11.1%	4,662,402	SC 13D
Feb 14, 2023	biotechnology value fund l p	10.6%	4,443,423	SC 13G/A
Feb 14, 2023	redmile group, llc	6.4%	2,684,396	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	0.1%	26,894	SC 13G/A
Feb 14, 2023	deep track capital, lp	6.50%	2,727,606	SC 13G/A

Recent SEC filings of Repare Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 26, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Repare Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Repare Therapeutics Inc News

Latest updates

Repare Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	504.3%	13,047,000	2,159,000	30,249,000	24,223,500	18,198,000	112,545,000	56,476,500	408,000	6,877,000	278,000	279,000	166,000	-
Operating Expenses	8.2%	43,914,000	40,577,000	42,507,000	40,359,000	37,830,000	39,146,000	39,413,000	35,237,000	35,611,000	31,957,000	26,946,000	21,746,000	17,212,000
S&GA Expenses	9.9%	8,648,000	7,868,000	8,719,000	8,529,000	7,939,000	7,904,000	7,938,000	8,779,000	7,639,000	6,596,000	6,741,000	5,237,000	4,795,000
R&D Expenses	7.8%	35,266,000	32,709,000	33,788,000	31,830,000	29,891,000	31,242,000	31,475,000	26,458,000	27,972,000	25,361,000	20,205,000	16,509,000	12,417,000
EBITDA Margin	-Infinity%	-1.92	-	0.25	-0.06	-0.08	-0.26	-2.67	-15.28	-14.06	-16.59	-19.99	-31.23	-397
Income Taxes	101.2%	190,000	-16,299,000	3,110,000	3,616,000	15,028,000	54,000	33,000	32,000	-412,000	-708,000	-421,000	-137,000	-1,554,000
Earnings Before Taxes	20.9%	-27,840,000	-35,178,000	-8,836,000	-31,325,000	-16,630,000	75,515,000	-38,060,000	-34,725,000	-28,702,000	-31,600,000	-26,730,000	-21,554,000	-16,817,000
EBT Margin	-56.5%	-2.02	-1.29	0.20	-0.09	-0.11	-0.29	-2.71	-15.53	-14.29	-16.87	-20.36	-31.85	-
Net Income	-48.5%	-28,030,000	-18,879,000	-11,946,000	-34,941,000	-31,658,000	75,461,000	-38,093,000	-34,757,000	-28,290,000	-30,892,000	-26,309,000	-21,417,000	-15,263,000
Net Income Margin	-34.3%	-1.83	-1.37	-0.03	-0.26	-0.22	-0.28	-2.69	-15.33	-14.07	-16.37	-19.84	-31.10	-
Free Cashflow	13.1%	-28,554,000	-32,870,000	-35,411,000	-32,261,000	-27,917,000	87,892,000	-29,762,000	-30,493,000	-20,903,000	-33,097,000	-18,487,000	-14,999,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-11.3%	254	286	302	336	364	409	308	337	369	296	321	339	357	370	382	103
Current Assets	-11.4%	244	275	292	326	354	391	290	319	351	280	309	328	347	361	377	99.00
Cash Equivalents	3.6%	111	107	116	121	160	155	276	305	334	261	294	312	326	348	370	95.00
Net PPE	-10.7%	4.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	6.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00
Liabilities	-21.2%	42.00	53.00	56.00	85.00	85.00	103	83.00	78.00	80.00	77.00	76.00	71.00	70.00	69.00	68.00	13.00
Current Liabilities	-20.2%	39.00	49.00	53.00	81.00	79.00	62.00	39.00	34.00	35.00	23.00	23.00	12.00	11.00	10.00	10.00	4.00
Shareholder's Equity	-9.1%	212	233	245	251	280	306	226	259	288	218	245	268	287	301	314	-
Retained Earnings	-9.2%	-333	-305	-286	-274	-239	-207	-283	-245	-210	-181	-151	-124	-103	-88.09	-74.34	-49.94
Additional Paid-In Capital	11.3%	62.00	56.00	49.00	43.00	37.00	32.00	27.00	23.00	18.00	14.00	11.00	8.00	6.00	5.00	4.00	4.00
Shares Outstanding	0.1%	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	37.00	37.00	37.00	-	-	-	-
Float	-	-	-	383	-	-	-	455	-	-	-	812	-	-	-	704	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	14.3%	-28,156	-32,870	-34,346	-31,786	-29,637	88,158	-28,193	-30,006	-20,738	-32,773	-18,058	-14,227	-12,947	-20,104	36,684	-9,717	-	-	-
Share Based Compensation	-0.3%	6,359	6,377	6,265	6,062	5,138	5,053	4,745	4,755	3,896	3,693	3,183	2,057	1,006	871	389	271	-	-	-
Cashflow From Investing	30.1%	31,879	24,498	28,350	-6,686	34,058	-208,930	-1,309	403	-398	-389	-117	-772	-9,247	-473	-13.00	-30.00	-	-	-
Cashflow From Financing	-63.0%	105	284	40.00	413	165	269	205	241	94,562	363	449	183	289	-1,695	249,026	222	-	-	-

RPTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Collaboration agreements	$ 51,133	$ 131,830
Operating expenses:
Research and development, net of tax credits	133,593	119,066
General and administrative	33,764	32,560
Total operating expenses	167,357	151,626
Loss from operations	(116,224)	(19,796)
Other income (expense), net
Realized and unrealized gain (loss) on foreign exchange	(170)	308
Interest income	13,334	5,631
Other expense, net	(119)	(43)
Total other income, net	13,045	5,896
Loss before income taxes	(103,179)	(13,900)
Income tax benefit (expense)	9,383	(15,147)
Net loss	(93,796)	(29,047)
Unrealized gain (loss) on available-for-sale marketable securities	456	(428)
Total other comprehensive income (loss)	456	(428)
Comprehensive loss	$ (93,340)	$ (29,475)
Net loss per share attributable to common shareholders--basic	$ (2.23)	$ (0.69)
Net loss per share attributable to common shareholders--diluted	$ (2.23)	$ (0.69)
Weighted-average common shares outstanding-basic	42,093,293	41,922,042
Weighted-average common shares outstanding-diluted	42,093,293	41,922,042

RPTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 111,268	$ 159,521
Marketable securities	112,359	184,420
Income tax receivable	10,813	0
Other current receivables	4,499	4,323
Prepaid expenses	4,749	5,715
Total current assets	243,688	353,979
Property and equipment, net	4,215	4,228
Operating lease right-of-use assets	3,326	5,371
Income tax receivable	2,276	0
Other assets	396	497
TOTAL ASSETS	253,901	364,075
Current liabilities:
Accounts payable	2,400	461
Accrued expenses and other current liabilities	24,057	21,645
Operating lease liabilities, current portion	2,400	2,171
Deferred revenue, current portion	10,222	53,102
Income tax payable	0	1,240
Total current liabilities	39,079	78,619
Operating lease liabilities, net of current portion	1,010	3,257
Deferred revenue, net of current portion	1,730	2,682
TOTAL LIABILITIES	41,819	84,558
Commitments and Contingencies
SHAREHOLDERS' EQUITY:
Preferred shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022, respectively; 0 shares issued and outstanding as of December 31, 2023, and December 31, 2022, respectively	0	0
Common shares, no par value per share; unlimited shares authorized as of December 31, 2023 and December 31, 2022; 42,176,041 and 42,036,193 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	483,350	482,032
Additional paid-in capital	61,813	37,226
Accumulated other comprehensive loss	28	(428)
Accumulated deficit	(333,109)	(239,313)
TOTAL SHAREHOLDERS' EQUITY	212,082	279,517
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 253,901	$ 364,075

About Repare Therapeutics Inc

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase Ã‚Â½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase Ã‚Â½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

CEO	Mr. Lloyd Mitchell Segal
WEBSITE	reparerx.com
INDUSTRY	Biotechnology
EMPLOYEES	180

Repare Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Repare Therapeutics Inc? What does RPTX stand for in stocks?

RPTX is the stock ticker symbol of Repare Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repare Therapeutics Inc (RPTX)?

As of Fri Apr 19 2024, market cap of Repare Therapeutics Inc is 132.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers.

What is the fair value of RPTX stock?

You can check RPTX's fair value in chart for subscribers. The fair value of Repare Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Repare Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Repare Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether RPTX is over valued or under valued. Whether Repare Therapeutics Inc is cheap or expensive depends on the assumptions which impact Repare Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPTX.

What is Repare Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, RPTX's PE ratio (Price to Earnings) is -1.42 and Price to Sales (PS) ratio is 2.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPTX PE ratio will change depending on the future growth rate expectations of investors.